menu ☰
menu ˟

De-escalating dose of bevacizumab may be effective in treating ROP

22 Nov 2017
NEW ORLEANS — A dose of intravitreal bevacizumab as low as 0.031 mg was successful in treating acute, severe retinopathy of prematurity in a small cohort of infant patients, a speaker said here.“Doses as low as 5% of what was used and considered ...

Click here to view the full article which appeared in Opthalmology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.